TD Cowen Keeps Hold on Beta Bionics at $17 After FDA Warning Letter; Financials and Q4 Revenue Provide Cushion
TD Cowen has reiterated a Hold rating and a $17.00 price target on Beta Bionics (BBNX) after the company received an FDA Warning Letter. The firm’s initial read suggests the letter does not impose burdensome remediation demands and will not block product sales or 510(k) submissions. Beta Bionics reported preliminary fourth-quarter 2025 revenue of a…